Tomlinson B, Bompart F, Graham B R, Liu J B, Prichard B N
Department of Clinical Pharmacology, University College, School of Medicine, London, United Kingdom.
Drugs. 1988;36 Suppl 6:37-47. doi: 10.2165/00003495-198800366-00008.
There is conflicting evidence regarding the main mechanism of the vasodilating effect with carvedilol at therapeutic doses, and to examine this, single doses of carvedilol 50mg and 100mg were compared with labetalol 400mg, propranolol 160mg, propranolol 80mg plus hydralazine 50mg and placebo in healthy subjects. Dose-response studies (required to increase heart rate or systolic blood pressure by 25 beats/min and 20mm Hg, respectively) were performed with phenylephrine, angiotensin and isoprenaline after each drug, and placebo administration and the effects of physiological pressor stimuli were compared. Phenylephrine systolic pressure dose-response curves were shifted by labetalol (dose ratio 2.4) and both carvedilol doses (dose ratios 50mg 1.9, 100mg 20.2). The slight shift to the right of the angiotensin dose-response curves with hydralazine plus propranolol (dose ratio 1.4) and carvedilol 50mg (dose ratio 1.4) was not significant. beta-Blockade was greatest with propranolol 160mg, followed by carvedilol 100mg, propranolol 80mg plus hydralazine 50mg, carvedilol 50mg and was least with labetalol 400mg (isoprenaline dose ratios required to increase heart rate by 25 beats/min were 55.2, 27.2, 20.2, 14.2, 11.5, respectively). Blood pressure rise with cold pressor and isometric exercise was inhibited most by labetalol. At these acute doses carvedilol displayed some alpha-blockade, but the lower ratio of alpha-blockade to beta-blockade differed from that seen with labetalol, which may account for the different haemodynamic responses at rest and during physiological pressor stimuli with the 2 drugs. There was no definite evidence of direct vasodilator effect.
关于卡维地洛治疗剂量下血管舒张作用的主要机制,存在相互矛盾的证据。为了对此进行研究,在健康受试者中,将单剂量的50mg和100mg卡维地洛与400mg拉贝洛尔、160mg普萘洛尔、80mg普萘洛尔加50mg肼屈嗪以及安慰剂进行了比较。在每种药物、安慰剂给药后,用去氧肾上腺素、血管紧张素和异丙肾上腺素进行剂量反应研究(分别需要将心率或收缩压提高25次/分钟和20mmHg),并比较生理升压刺激的效果。拉贝洛尔(剂量比2.4)以及两种卡维地洛剂量(50mg剂量比1.9,100mg剂量比2.02)使去氧肾上腺素收缩压剂量反应曲线发生了偏移。肼屈嗪加普萘洛尔(剂量比1.4)和50mg卡维地洛(剂量比1.4)使血管紧张素剂量反应曲线轻微右移,但不显著。160mg普萘洛尔的β受体阻滞作用最强,其次是100mg卡维地洛、80mg普萘洛尔加50mg肼屈嗪、50mg卡维地洛,400mg拉贝洛尔的β受体阻滞作用最弱(使心率增加25次/分钟所需的异丙肾上腺素剂量比分别为55.2、27.2、20.2、14.2、11.5)。拉贝洛尔对冷加压和等长运动引起的血压升高抑制作用最强。在这些急性剂量下,卡维地洛表现出一些α受体阻滞作用,但α受体阻滞与β受体阻滞的较低比值与拉贝洛尔不同,这可能解释了两种药物在静息状态和生理升压刺激期间不同的血流动力学反应。没有明确证据表明存在直接血管舒张作用。